Abstract:Figure S1ï¼šHDAC distribution in HeLa cells. Figure S2ï¼šEnzyme activity of peptides in SIRT1. Figure S3: CD spectra of peptide 16cyc-HxA, 16lin-HxA, 13cyc-HxA and 13lin-HxA. Figure S4: Enzyme activity of peptides in HDAC1, 3, 6, 8. Figure S5: Cellular uptake in cancer stem-like cells treated with peptide inhibitors for 4 hours. Figure S6: The transfection efficiency of peptides in cancer cells concluded from cell flow cytometry assays Figure S7: Cellular uptake in HeLa cells treated with different peptides for 4 hours. Figure S8: Cellular uptake in A549 cells treated with different peptides for 4 hours Figure S9: Time tracking of peptide cell stability in PA-1 cells treated with 10 Î¼M FITC-labeled peptides Figure S10: The comparison of cellular permeability and anti-proliferation effect in PA-1 cells treated with 16cyc-HxA and the scramble peptides Scr-1 and Scr-2. Figure S11: Anti-proliferation effect of different small inhibitors in cancer stem like cells and normal cells. Figure S12: LDH release from PA-1 cells for 4 hours and 12 hours. Figure S13: Hemolysis assays were performed to assess the erythrocyte toxicity of peptide inhibitors. Figure S14: The peptide binding affinity towards these endogenous HDAC isoforms using SA pull down assays. Figure S15: HDACs expression affected by peptide inhibitors in cancer stem-like cells and HDAC activity in A549 cells treated with peptide inhibitors. Figure S16: The irreversible inhibition of HDACs in PA-1 cell lines for 48 hours' treatment. Figure S17: The validation of HDAC inactivation using HDAC selective small inhibitors as positive controls. Figure S18: The quantifying of the different protein levels from Fig 4C. Figure S19: Peptide inhibitors could alter the recruitment of HDAC1 and LSD1 to Sox2 gene promoters by ChIP experiment in PA-1 cells. Figure S20: Apoptotic cells stained with FITC-Annexin V/PI (propidium iodide) were measured by flow cytometry. Figure S21ï¼šThe western blot assays were performed to confirm the caspase-3 dependent apoptosis in PA-1 cells Figure S22ï¼šCell cycle distribution of flow cytometry analysis treated with different peptides. Figure S23: The expression of cell cycle regulatory proteins in PA-1 cells treated with different peptide inhibitors. Figure S24: Transcriptome analysis of PA-1 cells treated with different inhibitors Figure S25: 2D diagram to show the number of genes with change of expression level and gene ontology analysis in PA-1 cells treated with different peptides. Figure S26: The relative genes were selected for RT-PCR assays to valid the results of RNA-microarray analysis. Figure S27ï¼šThe protein levels of EGFR and WNT5A1 in PA-1 cells treatment with peptide inhibitors Figure S28: The cage-wheel exercise assay was performed to study the motor learning ability of mice. Figure S29: The antitumor activities of peptides and SAHA in a NTERA-2 xenograft animal model Figure S30: The body distribution of Cy-5 labeled peptides 16cyc-HxA, 16lin-HxA and PBS at different time points after intratumor injections. Figure S31: Hematoxylin and eosin (H&E) staining of organs and tumor sections collected from different groups of mice 3 weeks after treatment Figure S32: Immunohistochemistry analysis of HDAC1 and HDAC6 and their related protein level in tumor tissue slides. Figure S33: The proliferative index was tested by doing KI67 staining on PA-1 tumor tissues. Table S1: Peptides Characterization. Table S2: Primer sequence of genes for RT-PCR analysis Table S3: Sequences of primers used for ChIP assays Table S4: Cancer related genes affect by HDAC inhibitor 16cyc-HxA in PA-1 cells.

Potent Inhibition of HIF1α and p300 Interaction by a Constrained Peptide Derived from CITED2

Inhibition of Hypoxia-Inducible Transcription Factor (Hif-1Α) Signaling with Sulfonyl-γ-AApeptide Helices.

Engineered coiled-coil HIF1α protein domain mimic

Treating ICB-resistant cancer by inhibiting PD-L1 via DHHC3 degradation induced by cell penetrating peptide-induced chimera conjugates

A cyclic peptide-based PROTAC induces intracellular degradation of palmitoyltransferase and potently decreases PD-L1 expression in human cervical cancer cells

Optimization of Peptidomimetics as Selective Inhibitors for the β-Catenin/T-Cell Factor Protein-Protein Interaction.

A Dimethylbromobenzene-Cysteine Stapled Peptide Dual Inhibitor of the P53-Mdm2/mdmx Interactions

Homology Modeling and Molecular Dynamics Simulation of the HIF2α Degradation-Related HIF2α-VHL Complex.

Identification of small molecule compounds that inhibit the HIF-1 signaling pathway

The Development of CDC25A-Derived Phosphoseryl Peptides That Bind 14-3-3ε with High Affinities

Design and Evaluation of Α-Helix-based Peptide Inhibitors for Blocking PD-1/PD-L1 Interaction.

Disrupting the intramolecular interaction between proto-oncogene c-Src SH3 domain and its self-binding peptide PPII with rationally designed peptide ligands.

Optimization of Beclin 1-Targeting Stapled Peptides by Staple Scanning Leads to Enhanced Antiproliferative Potency in Cancer Cells

Rational design of peptide inhibitors targeting HSP90–CDC37 protein–protein interaction

Structural Basis for High-Affinity Peptide Inhibition of P53 Interactions with MDM2 and MDMX.

Supplementary Data from Stabilized Peptide HDAC Inhibitors Derived from HDAC1 Substrate H3K56 for the Treatment of Cancer Stem–Like Cells <i>In Vivo</i>

Α-Helix-mimicking Sulfono-γ-AApeptide Inhibitors for P53–mdm2/mdmx Protein–Protein Interactions

Data from Stabilized Peptide HDAC Inhibitors Derived from HDAC1 Substrate H3K56 for the Treatment of Cancer Stem–Like Cells in Vivo

A Perylene Derivative Regulates HIF-1α and Stat3 Signaling Pathways

Stapled peptide PROTAC induced significantly greater anti-PD-L1 effects than inhibitor in human cervical cancer cells